Currently, there are 40.21M common shares owned by the public and among those 33.16M shares have been available to trade.
The company’s stock has a 5-day price change of 18.72% and 9.24% over the past three months. ORMP shares are trading 7.44% year to date (YTD), with the 12-month market performance down to -3.35% lower. It has a 12-month low price of $2.00 and touched a high of $3.67 over the same period. ORMP has an average intraday trading volume of 159.73K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 14.66%, 10.18%, and 9.59% respectively.
Institutional ownership of Oramed Pharmaceuticals, Inc (NASDAQ: ORMP) shares accounts for 19.58% of the company’s 40.21M shares outstanding.
It has a market capitalization of $104.81M and a beta (3y monthly) value of 1.60. The stock’s trailing 12-month PE ratio is 23.85, while the earnings-per-share (ttm) stands at $0.11. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.13% over the week and 4.75% over the month.
Analysts forecast that Oramed Pharmaceuticals, Inc (ORMP) will achieve an EPS of -0.07 for the current quarter, -0.05 for the next quarter and -0.26 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.07 while analysts give the company a high EPS estimate of -0.07. Comparatively, EPS for the current quarter was 0.33 a year ago. Earnings per share for the fiscal year are expected to decrease by -277.78%, and 50.00% over the next financial year.
Looking at the support for the ORMP, a number of firms have released research notes about the stock. Canaccord Genuity stated their Hold rating for the stock in a research note on January 12, 2023, with the firm’s price target at $30-$3. Cantor Fitzgerald coverage for the Oramed Pharmaceuticals, Inc (ORMP) stock in a research note released on February 18, 2022 offered a Overweight rating with a price target of $20. Alliance Global Partners on their part issued Buy rating on December 03, 2020.
